Objective: Natalizumab is a humanized recombinant monoclonal antibody against very late activation antigen-4 approved for the treatment of patients with multiple sclerosis (MS). A phase II study failed to demonstrate a difference between natalizumab treatment groups and the placebo group with regard to gadolinium enhancing lesions on MRI 3 months after discontinuation of therapy. The objective of this study was to assess clinical MS disease activity, surrogate disease markers on MRI, immunologic parameters in peripheral blood and CSF, as well as safety in patients with MS after discontinuation of natalizumab therapy.
Natalizumab is a humanized monoclonal antibody that binds to the ␣ 4 chain of the ␣ 4 ␤ 1 (very late activation antigen 4 ) and ␣ 4 ␤ 7 integrins. 1 Based on the results of two phase III clinical trials, 2, 3 natalizumab was originally approved by the Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis (MS) on November 24, 2004. Subsequently, two patients with MS who had been enrolled in the SENTINEL phase III trial were diagnosed with progressive multifocal leukoencephalopathy (PML). 4, 5 Another patient with Crohn disease who had been treated with natalizumab in the context of clinical trials was later also diagnosed with PML. 6 The purpose of this study was to assess MS disease activity with regard to relapse rate and accumulation of neurologic disability after discontinuation of natalizumab. Also, we quantified surrogate markers of MS disease activity by MRI, as well as immunologic parameters in peripheral blood and CSF.
Supplemental data at www.neurology.org METHODS Patients. Details on our patient cohort and control cohorts were previously reported. 7, 8 Written informed consent was obtained, and all study procedures were approved by the IRB.
Lymphocyte counts. Absolute cell numbers in peripheral blood were determined by a commercial clinical laboratory. CSF cells were counted as previously reported. 7, 8 Flow cytometry. PBMC were stained for flow cytometry and analyzed using standard methods. 7, 8 Biomarkers of humoral immunity. CSF and serum were examined for protein, albumin, and immunoglobulin G, A, and M levels by nephelometry (BN II; Behring, Marburg, Germany). The specific intrathecal production of IgG, IgA, and IgM was calculated according to the Reiber formula. 9 CSF and serum were analyzed for oligoclonal bands (OCBs) by isoelectric focusing and IgG immunoblot (Titan Gel; Rolf Greiner Biochemica, Flacht, Germany).
Assessment of patient safety and clinical disease activity. The annual relapse rate was assessed in 21 patients for the 12-month period prior to enrollment into the AFFIRM and SENTINEL trials, for the trial period of the trials, and for the 14-month period after cessation of natalizumab (Tysabri). Neurologic disability assessed by the Expanded Disability Status Scale (EDSS) 10 was recorded in 17 patients prior to enrollment into the AFFIRM and SENTINEL trial, at the time of cessation of natalizumab therapy, and 14 months after cessation of natalizumab. At these time points, study patients were seen and assessed for the occurrence of clinical relapses, infections, and any unexpected medical complications. In addition, at months 3, 9, and 12 after cessation of natalizumab therapy, patients were contacted by telephone.
Evaluation of MR images. Images from 16 patients were analyzed using a dual echo fast/turbo spin echo sequence giving scans with proton density, T1, and T2-weighted contrast while the patients were on natalizumab, and 14 months after cessation of therapy. All scans were performed at 1.5 Tesla.
Statistical analysis. Mann-Whitney U paired test and Wilcoxon
matched pair test were utilized to compare samples not independent of each other. GEE analysis was utilized to analyze recurrent event data. Prisms 4 (San Diego, CA) and SAS 9.1.3 (Cary, NC) software were used for data analyses. p Values Ͻ0.05 were considered significant.
RESULTS

Participants. The table summarizes the patient characteristics.
Peripheral blood leukocyte and lymphocyte counts. Total white blood cell (WBC) numbers in peripheral blood of natalizumab-treated patients with MS at study entry were within normal limits (figure 1A). A serial cross-sectional analysis of all study participants showed a nonsignificant decrease in leukocyte numbers at month 6, and at month 14 after cessation of natalizumab. There was also a significant increase in the number of CD4ϩ T cells, CD8ϩ T cells, and CD19ϩ B cells in peripheral blood 14 months after discontinuation of natalizumab therapy (figure 1, B-D), whereas the number of CD138ϩ plasma cells did not change ( figure 1E ). CD4:CD8 T cell ratios in peripheral blood remained within normal limits (figure 1F).
A longitudinal analysis showed a significant decrease of WBC between study entry and month 14 ( figure 1G ). It also confirmed the increase of CD4ϩ T cells in peripheral blood 14 months after study entry, following an initial decrease at 6 months after cessation of natalizumab ( figure  1H ). The number of CD8ϩ T cells did not change over the 14-month study period, but there was an initial significant decrease 6 months after cessation of natalizumab (figure 1I).
There was no correlation between the numbers of natalizumab doses received and cell numbers within peripheral blood and CSF (data not shown). There was also no difference in the number of cells between patients previously enrolled in the AFFIRM or SENTINEL trial (data not shown). CSF lymphocyte counts and phenotypes. A serial cross-sectional analysis of all study participants showed significantly fewer WBC, CD4ϩ T cells, CD8ϩ T cells, CD19ϩ B cells, and CD138ϩ plasma cells in CSF from natalizumab-treated patients with MS compared to patients with MS who had never received natalizumab therapy (figure e-1 on the Neurology ® Web site at www.neurology.org), After an initial decrease at 6 months after cessation of natalizumab, there was an increase of CD4ϩ T cells in the PB 14 months after study entry (H). The number of CD8ϩ T cells did not change over the 14-month study period, but there was an initial significant decrease 6 months after cessation of natalizumab (I).
as well as 6 months after cessation of natalizumab treatment (figure e-1). In contrast, 14 months after discontinuation of natalizumab, there was no significant difference in cell numbers between these cohorts (figure e-1). This was still true if the two patient outliers with the highest cell numbers at the 14-month time point were excluded from the analysis (data not shown). The CD4:CD8 T cell ratio in CSF, which was reversed in patients with MS who were treated with natalizumab, normalized 6 months after discontinuation of therapy, and remained normal after 14 months (figure e-1). A longitudinal analysis of those patients showed very similar results (figure e-1).
Humoral immune parameters in the CSF. Two examples of OCBs are shown in figure 2A . The number of OCBs, the amount of intrathecally synthesized IgG, and the CSF/serum albumin quotient did not differ between patients on natalizumab, 6 months, or 14 months after cessation of the drug (figure 2, B, D, and E) . The total amount of intrathecal IgG increased significantly 6 months after cessation of natalizumab, and remained stable over the next 8 months ( figure 2C ).
Patient safety.
No serious adverse events were recorded during the 14-month time period after the cessation of natalizumab therapy.
Clinical disease activity. There was a significant decrease in the annual relapse rate in patients with MS on natalizumab during the AFFIRM and SENTI-NEL trials and during the 14-month period compared to the pretrial period ( figure 3A ). There was no significant difference with regard to neurologic disability as assessed by the EDSS scale among the three time points in this patient cohort ( figure 3B ).
Disease activity on MRI.
There was no significant difference with regard to gadolinium-enhancing (Gdϩ) lesions on T1-weighted images, and the total lesion volume on T2-weighted and FLAIR weighted images between patients on natalizumab and 14 months after cessation of treatment (figure 3, C-E).
DISCUSSION
The pharmacodynamic duration of natalizumab is important for several reasons. In the context of a phase II clinical trial, it was shown that as early as 3 months after discontinuation of natalizumab there was no difference between the treatment group and the placebo groups with regard to Gdϩ lesions. 11 Another group of investigators recently showed an increase in T2-weighted lesion activity on cerebral MR images in a cohort of 21 patients 15 months after cessation of natalizumab therapy. 12 Thus, there is at least a theoretical concern that the discontinuation of natalizumab therapy may rapidly lead to a loss of its beneficial clinical effects, or even to a rebound phenomenon. Our own data do not support these concerns. Specifically, we did not observe a worsening of radiographic or immunologic disease activity after cessation of natalizumab therapy. In the majority of our patients, we also did not observe deterioration in their clinical status. It is important to point out that in contrast to the phase II trial mentioned above, 11 the vast majority of patients in our cohort received other pharmacotherapies while involved in the SENTINEL combination trial, 2 as well as after discontinuing natalizumab (table) . The article by Vel- linga et al. does not comment on the use of other disease-modifying therapies in their patients. 12 We had shown earlier that patients with MS who are on natalizumab therapy as well as patients 6 months after discontinuation of natalizumab treatment have significantly decreased numbers of B cells and plasma cells in their CSF. It is intriguing that natalizumab therapy appears to have minimal effects on the total production of IgG in the CNS, and that there is no impact on the number of OCBs in the CSF. These observations may suggest that there are inflammatory lymphocytes in the CNS, including cells of the B cell lineage, that are present in the brain and spinal cord for long periods of time and independent of effects on further lymphocyte migration into the CNS.
The medical community is concerned with the risk of developing PML while on natalizumab therapy. 13 Our 14-month data demonstrate that immune surveillance in the peripheral blood and CSF may be restored, even in patients who receive other immunomodulatory therapy. Our patients did not experience any symptoms associated with PML, other opportunistic infections, or any serious treatment-related complications. Longitudinal analysis of the annual relapse rate was assessed in 21 patients with multiple sclerosis (MS) for the 12-month period prior to enrollment into the AFFIRM and SENTINEL trials (MS pre Nat), for the trial period of the AFFIRM and SENTI-NEL trials (MS Nat), and for the 14-month period after cessation of natalizumab (MS Nat 14 months) (A). In addition, neurologic disability assessed by the Expanded Disability Status Scale (EDSS) was recorded in 17 patients prior to enrollment into the AFFIRM and SENTINEL trial (MS pre Nat), at the time of cessation of natalizumab therapy (MS Nat), and 14 months after cessation of natalizumab (MS Nat 14 months) (B). There was a significant decrease in the annual relapse rate in patients with MS on natalizumab during the AFFIRM and SENTINEL trials compared to the pretrial period (A). There was also a significant decrease in the annual relapse rate in the 14-month period after cessation of therapy compared to the pretrial period (A). In contrast, there was no significant difference in the annual relapse rate between patients on natalizumab during the AFFIRM and SENTINEL trials and during the 14-month period after cessation of natalizumab therapy (A). There was no significant difference with regard to neurologic disability as assessed by the EDSS scale among the three time points in this patient cohort (B). The number of new gadolinium-enhancing (Gdϩ) lesions on T1-weighted MRI (C), the total lesion volume on T2-weighted (D) and FLAIR-weighted images (E) was assessed while patients received natalizumab, and 14 months after discontinuation of therapy. There was no significant difference with regard to Gdϩ lesions on T1weighted images (C) and the total lesion volume on T2-weighted (D) and FLAIR weighted images (E).
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